We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0HRT market cap is 0. The company's latest EPS is USD 0.0201 and P/E is 1.49.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 53.7M | 24.43M | 20.05M | 16.21M | 22.18M |
| Operating Income | -17.24M | -22.59M | -18.45M | -6.85M | 3.36M |
| Net Income | -16.64M | -22.28M | -15.55M | -9.13M | 3.1M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 52.69M | 30.63M | 18.07M | 12.74M | 9.2M |
| Total Liabilities | 23.54M | 19.41M | 14.52M | 13.51M | 6.3M |
| Total Equity | 29.15M | 11.21M | 3.54M | -777k | 2.9M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -2.23M | -7.3M | -7.49M | -1.89M | 2.25M |
| Investing | -1.15M | -1.06M | -85k | N/A | -156k |
| Financing | 47k | 3.27M | 4.37M | 1.12M | -1.39M |
| Market Cap | 0 |
| Price to Earnings Ratio | 1.49 |
| Price to Sales Ratio | 0.21 |
| Price to Cash Ratio | 3.53 |
| Price to Book Ratio | 1.6 |
| Dividend Yield | - |
| Shares Outstanding | 154.61M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Cv Sciences Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.cvsciences.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
